We are on a mission to accelerate drug discovery in oncology

We are on a mission to accelerate drug discovery in oncology

We are on a mission to accelerate drug discovery in oncology

The Orakl Oncology techbio platform partners with the oncology industry to meet the challenge of personalized medicine.

biology + data + AI → new anti-cancer drugs

biology + data + AI → new anti-cancer drugs

biology + data + AI → new anti-cancer drugs

The future of cancer treatment and drug development relies on recognizing that each tumor is different. Partnering with Gustave Roussy, the world's 3rd best cancer center, Orakl Oncology enables the emergence of rare oncology by connecting patient tumors to the drug discovery industry.

Orakl Oncology leverages tumor avatars that combine best-in-class biology with deep patient data, at scale. Our techbio platform partners with oncology players to identify relevant targets and deliver better drugs, faster.

The future of cancer treatment and drug development relies on recognizing that each tumor is different. Partnering with Gustave Roussy, the world's 3rd best cancer center, Orakl Oncology enables the emergence of rare oncology by connecting patient tumors to the drug discovery industry.

Orakl Oncology leverages tumor avatars that combine best-in-class biology with deep patient data, at scale. Our techbio platform partners with oncology players to identify relevant targets and deliver better drugs, faster.

Best-in-class biology

Best-in-class biology

Best-in-class biology

Our tumour models mimic real-life responses to drugs. They result from the exclusive know-how from more than 28 years of combined R&D.

Image credit to the Jaulin lab (S. Bedja, J. Cartry, E. Gontran, JB. Lopez)

Deep patient data

Deep patient data

Deep patient data

We match our tumour models with detailed clinical and omics data. This provides the necessary context to interpret biological results.

AI-powered analysis

AI-powered analysis

AI-powered analysis

We gather unique insights by mining multi-modal experimental data and combining it with deep patient data.

The founding team

The founding team

The founding team

Fanny
Jaulin, PhD
CEO & CSO

Weill Medical College 🇺🇸, MSKCC 🇺🇸, Inserm 🇫🇷, Gustave Roussy 🇫🇷, HEC 🇫🇷

Fanny is an experienced researcher and lab-leader with more than 20 years of research in cancer biology under her belt. She is excited by anything new provided that it can positively impact society and that she can listen to Daft Punk with her children.

Diane-Laure
Pagès, PhD
COO

Ecole polytechnique 🇫🇷, Ecole Normale Supérieure 🇫🇷, Gustave Roussy 🇫🇷, HEC 🇫🇷

Diane-Laure is an interdisciplinary engineer and researcher specialized in cancer biology. Her contributions have been recognized by multiple awards. Open-minded and well-organized, she cements the team and loves sailing, whatever the weather.

Gustave
Ronteix, PhD
CTO

Ecole polytechnique 🇫🇷, Cambridge University 🇬🇧, Institut Pasteur 🇫🇷

Gustave is passionate about automating biology. He's an engineer and a researcher specialized in microfluidics, immuno-oncology and quantitative biology. He enjoys socials with colleagues and friends before heading to the rugby pitch.

They support us

They support us

They support us

Made with ❤️ and without cookies.

Write to us at contact@orakl-oncology.com

Orakl Oncology SAS

39 rue Camille Desmoulins

94800 Villejuif, France

SIREN: 948.448.972

Made with ❤️ and without cookies.

Write to us at contact@orakl-oncology.com

Orakl Oncology SAS

39 rue Camille Desmoulins

94800 Villejuif, France

SIREN: 948.448.972

Made with ❤️ and without cookies.

Write to us at contact@orakl-oncology.com

Orakl Oncology SAS

39 rue Camille Desmoulins

94800 Villejuif, France

SIREN: 948.448.972